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Who Are theWomen Most Vulnerable to Malaria?
Sub-Saharan Africa (SSA) is considered the be the centre of the global HIV epidemic with the
highest prevalence and incidence of HIV infection globally and where women account for
approximately 57% of all people living with HIV [1]. SSA also concentrates the greatest burden
of malaria. In this region, approximately 30 million pregnancies occur annually in areas of
intense Plasmodium falciparum transmission, and HIV-infected women are known to be the
most vulnerable to malaria infection [2,3].
For reasons not completely understood, pregnant women are particularly vulnerable to
malaria, with more frequent and higher density infections than nonpregnant women. Malaria
in pregnancy is associated with significant maternal and infant morbidity and mortality [4]. Of
note, an estimated 20 million HIV-infected individuals in SSA live in malaria endemic areas,
and over 12 million are women of reproductive age [1]. In addition, approximately one million
pregnancies each year are complicated by coinfection with malaria and HIV in SSA [1]. As a
group, women in this region are the most vulnerable to HIV infection due to biological and
sociocultural factors [3]. As with malaria, maternal HIV infection increases the risk of miscar-
riage, stillbirth, and other adverse birth outcomes [5]. The interaction between the two infec-
tions is particularly deleterious in pregnancy. HIV increases the severity of malaria infection
and disease, and malaria infection increases HIV viral load, which in some studies has been
shown to increase the risk of mother-to-child transmission of HIV (MTCT-HIV)[6].
Summary Points
• African HIV-infected pregnant women are the most vulnerable population group to
malaria infection.
• Paradoxically, these women are also the least protected against malaria due to fear of
potential interactions between antiretroviral and antimalarial drugs.
• Action is urgently needed to evaluate antimalarials that can be safely administered to
HIV-infected pregnant women on antiretroviral treatment and cotrimoxazole
prophylaxis.
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Are Current Malaria Control Strategies Sufficiently Effective for
HIV-Infected Pregnant Women?
The current WHO recommendation for control of malaria in pregnant women living in stable
transmission areas relies on both the administration of Intermittent Preventive Treatment with
sulfadoxine-pyrimethamine (IPTp-SP) beginning as early as possible in the second trimester
and at every scheduled antenatal care (ANC) visit thereafter, along with the use of insecticide-
treated bed nets (ITNs) [7]. However, in HIV-infected women, IPTp-SP is contraindicated to
avoid the potentially serious drug interactions with concomitant cotrimoxazole prophylaxis
(CTXp), which is currently recommended in all HIV-infected pregnant women to prevent
opportunistic infections [8]. Thus, even though IPTp-SP is a life-saving and highly cost-effec-
tive intervention, it cannot be used in the most vulnerable group, HIV-infected women [9,10].
Because of the proven antimalarial effect of cotrimoxazole, it has been assumed that CTXp
would provide effective malaria prevention in HIV-infected pregnant women [11]. However,
evidence to support this assumption is sparse and requires additional confirmation [12]. In
addition, programmatic effectiveness of CTXp may be suboptimal due to the challenges of
adherence to a daily regimen of indefinite duration [13]. In a recent study, the addition of an
efficacious antimalarial drug (mefloquine) to CTXp in HIV-infected pregnant women
improved malaria prevention as evidenced by reductions in peripheral parasitemia and placen-
tal infection, as well as improvement in overall maternal health with decreased hospital admis-
sions [6]. However, mefloquine prophylaxis was not well tolerated, and importantly, was found
to be associated with both an increased maternal HIV viral load at delivery and risk of
MTCT-HIV. In this study, most of the nonobstetric admissions among HIV-infected women
were due to infectious diseases, which are known to be an important cause of maternal death in
these women [6]. The immunosuppressive effect of malaria is well documented; therefore, the
effective prevention of malaria could help to reduce the risk of opportunistic infections. The
effect of malaria as a risk factor for death in HIV-infected individuals is increasingly recog-
nised, and it has been recently reported among HIV-infected children in Malawi [14].
Unfortunately, the assumption that HIV-infected pregnant women are well protected
against malaria by CTXp has curtailed evaluation of other drugs for this purpose [15,16]. Of
note, prevention of MTCT-HIV through lifelong administration of antiretroviral therapy
(ART) to HIV-infected pregnant women (termed “option B+”), as well as the recent WHO rec-
ommendation to initiate ART for every HIV-infected individual regardless of the CD4 cell
count (“treat all”), should lead to an increase in the survival and therefore number of HIV-
infected women of reproductive age [8,17]. This may lead to an increase in the number of
women who become pregnant and are exposed to malaria in endemic areas. In this context, the
lack of specifically designed studies to evaluate additional malaria prevention strategies in this
special population means that the most vulnerable women are also the least protected. Thus,
studies are needed in HIV-infected pregnant women in endemic areas in SSA to evaluate
improved malaria prevention tools, including alternative antimalarial drugs. These studies
should include (or be preceded by) careful assessment of potential pharmacological and safety
interactions between antimalarial and antiretroviral drugs.
What Are the Challenges and theWay Forward?
Pregnancy itself increases the complexity of the clinical management of the malaria-HIV coin-
fection by reducing the therapeutic options and by altering the function of drug-metabolizing
enzymes and drug transporters in a gestational-stage and tissue-specific manner [18,19].
Recent pharmacokinetic studies indicate that a significant reduction in systemic exposure to
some antiretroviral and antimalarial drugs may occur when administered concomitantly,
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raising concerns about an increased risk of treatment failures and/or safety issues [20,21].
These disturbing results point to the need for further investigation to evaluate the clinical rele-
vance of these drug–drug interactions in pregnancy.
More generally, as new policies such as “treat-all” and “option B+” are scaled up, new and
complex public health challenges may appear due to the increasing number of HIV-infected
people who would be exposed to ART. For example, it would be important to implement active
pharmacovigilance systems in some sentinel sites to monitor possible drug-related adverse
events, as well as to reinforce the health system to guarantee the sustainability of ART adminis-
tration to all HIV-infected individuals and long-term treatment adherence to prevent the
appearance of viral mutants of resistance. Moreover, in malaria-endemic areas, HIV-infected
individuals—in addition to being more likely to receive antimalarial drugs for treatment due to
their increased risk of malaria—may also be receiving these drugs for prevention; examples
include seasonal malaria chemoprevention or mass drug administration during malaria elimi-
nation efforts. Thus, the problem of malaria–HIV coinfection needs to be revisited to take into
account the new context and evolving intervention strategies for both diseases.
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